Annovis Bio partners with Weave Bio on AI platform to support planned buntanetap Alzheimer’s NDA submission
ANVS•Phase 3 study timing and enrollment
The pivotal Phase 3 Alzheimer’s study enrolled 862 biomarker-confirmed patients versus a 760 target.
Database lock is targeted for December 2026; top-line symptomatic data are expected in March 2027.
Collaboration to support NDA preparation
Annovis Bio entered a collaboration with Weave Bio to support preparation of a planned U.S. NDA for Alzheimer’s drug candidate buntanetap.
Weave’s AI platform will be used to draft, review, and manage NDA documents ahead of the Phase 3 trial’s 6-month top-line readout.
Annovis retains responsibility for content, verification, and final approval of all documents submitted to the FDA.
